Clinical trial
rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated…
NCT00572156 · Ipsen, Industry · Terminated
Key facts
| NCT number | NCT00572156 |
|---|---|
| Title | rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency |
| Official title | Recombinant Human Growth Hormone (rhGH) and Recombinant Human Insulin-like Growth Factor-1 rhIGF-1) Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency: A Six-year, Randomized, Multi-center, Open-label, Parallel-group, Active Treatment Controlled, Dose Selection Trial |
| Lead sponsor | Ipsen, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Insulin-like Growth Factor-1 Deficiency |
| Intervention type | Drug |
| Interventions | NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]) |
| Enrollment | 106 |
| Start date | Dec 1, 2007 |
| Primary completion | Apr 1, 2010 |
| Completion | Mar 1, 2012 |
| First posted | Dec 12, 2007 |
| Last update posted | Mar 30, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: